Preview

Атеротромбоз

Расширенный поиск

«СТАРЫЕ» И «НОВЫЕ» ВОЗМОЖНОСТИ ПРОФИЛАКТИКИ ИНСУЛЬТА У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ

https://doi.org/10.21518/2307-1109-2013-1-44-52

Полный текст:

Аннотация

.

Об авторе

А. Л. Комарова
НИИ кардиологии им. А. Л. Мясникова ФГБУ РКНПК МЗ РФ
Россия


Список литературы

1. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)//European Heart Journal. 2010. № 31. Р. 2369–2429.

2. Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation. A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association//Stroke. 2012. DOI: 10.1161/ STR.0b013e318266722a.

3. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association// European Heart Journal. 2012. № 33. Р. 2719–2747.

4. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [published correction appears//Arch Intern Med. 1994. № 154. Р. 2254; Arch Intern Med. 1994. № 154. Р. 1449–1457.

5. White H. D., Gruber M., Feyzi J., et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V//Arch Intern Med. 2007. Feb. 12. № 167 (3). Р. 239–245.

6. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med. 2009. № 361. Р. 1139–1151.

7. Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators. Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011. № 365. Р. 883–891.

8. Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators. Apixaban vs. warfarin in patients with atrial fibrillation. N Engl J Med. 2011. № 365. Р. 981–992.

9. Wallentin L., Yusuf S., Ezekowitz M. D., et al. Efficacy and safety of dabigatran compared with warfarin at diff erent levels of international normalised ratio control for stroke prevention in atrial fi brillation: an analysis of the RE-LY trial// Lancet. 2010. № 376. Р. 975–983.

10. Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines//CHEST. 2012. № 141 (2) (Suppl). Р. e44S–e88S.

11. Whitlon D. S., Sadowski J. A., Suttie J. W. Mechanism of coumarin action: signifi cance of vitamin K epoxide reductase inhibition. Biochemistry. 1978. № 17 (8). Р. 1371–1377.

12. Cannegieter S. C., Rosendaal F. R., Wintzen A. R., v an der Meer F. J., Vandenbroucke J. P., Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995. № 333 (1). Р. 11–17.

13. Abdelhafi z A. H., Wheeldon N. M. Results of an open-label, prospective study of anticoagulant therapy for atrial fi brillation in an outpatient anticoagulation clinic. Clin Ther. 2004. № 26 (9). Р. 1470–1478.

14. Veeger N. J. G.M., Piersma-Wichers M., Tijssen J. G. P., Hillege H. L., van der Meer J. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venousthromboembolism//Br J Haematol. 2005. № 128 (4). Р. 513–519.

15. Sudlow M., Thomson R., Thwaites B., et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community//Lancet, 1998. № 352. Р. 1167–71.

16. Brass L. M., Krumholz H. M., Scinto J. M., et al. Warfarin use among patients with atrial fibrillation// Stroke, 1997. № 28. Р. 2382–2389.

17. Go A. S., Hylek E. M., Borowsky L. H., et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study// Ann Intern Med. 1999. № 131. Р. 927–934.

18. Эрлих А. Д., Давыденко М. Н., Маслова Е. С., Саляхова Т. Ю. Мерцательная аритмия (фибрилляция предсердий) и антикоагулянтная терапия при ней в московской городской больнице. Однодневный скрининг. http://www.athero.ru/ AF-hosp_cross_sect-web.htm.

19. Witt D. M., Delate T., Garcia D. A., et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding//Arch Intern Med. 2012. Oct. 22. № 172 (19). Р. 1484–1491.

20. Blackshear J. L., Odell J. A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation//Ann Thorac Surg. 1996. № 61. Р. 755–759.

21. Атьков О. Ю., Атауллаханова Д. М., Быкова Е. С. Возможности чреспищеводной эхокардиографии в диагностике тромбоза ушка левого предсердия при мерцательной аритмии//Кардиология. 1999. № 12. Т. 39. С. 58–63.

22. Dawson A. G., Asopa S., Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? Interactive CardioVascular and Thoracic Surgery 10. 2010. Р. 306–311.

23. Healey J. S., Crystal E., Lamy A., et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke//Am Heart J 2005. № 150. Р. 288–293.

24. Salzberg S. P., Plass A., Emmert M. Y., et al. Left atrial appendage clip occlusion: early clinical results//J Thorac Cardiovasc Surg. 2010. № 139. Р. 1269–1274.

25. Ailawadi G., Gerdisch M. W., Harvey R. L., et al. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial//J Thorac Cardiovasc Surg. 2011. № 142. Р. 1002–9, 1009, e1.

26. Alli O., Holmes D. R. Left Atrial Appendage Occlusion for Stroke Prevention Curr Probl Cardiol 2012. № 37. Р. 405–441.

27. Nietlispach F., Gloekler S., Khattab A. et al. Percutaneous left atrial appendage closure// European Geriatric Medicine 3. 2012. Р. 308–311.

28. Ostermayer S. H., Reisman M., Kramer P. H. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high risk patients with non rheumatic atrial fi brillation: results from the international multicenter feasibility trials//J Am Card Coll Cardiol. 2005. № 46. Р. 9–14.

29. Sievert H., Lesh M. D., Trepels T., et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation – early clinical experience// Circulation. 2002. № 105. Р. 1887–1889.

30. Hanna I. R., Kolm P., Martin R., Reisman M., Gray W., Block P. C. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO) six-month echocardiographic follow-up//J Am Coll Cardiol. 2004. № 43. Р. 1868–1872.

31. Fountain R. B., Holmes D. R., Chandrasekaran K., et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial//Am Heart J. 2006. № 151. Р. 956–961.

32. Sick P. B., Schuler G., Hauptmann K. E., et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation//J Am Coll Cardiol. 2007. № 49. Р. 1490–95.

33. El-Chami M. F., Grow P., Eilen D., et al. Clinical outcomes three years after PLAATO implantation// Catheter Cardiovasc Interv. 2007. № 69. № 704–707.

34. Holmes D. R., Reddy V. Y., Turi Z. G. et al for the PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial// Lancet. 2009. № 374. Р. 534–542.

35. Reddy V. Y., Doshi Sh. K., Sievert H., et al on behalf of the PROTECT AF Investigators. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Followup of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial//Circulation. 2013. № 127. Р. 720–729.

36. Reddy V. Y., Holmes D., Doshi Sh. K., at al. Safety of Percutaneous Left Atrial Appendage Closure Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry// Circulation. 2011. № 123. Р. 417–424.

37. http://clinicaltrials.gov/show/NCT01182441

38. http://www.theheart.org/article/1515107. do?utm_medium=email&utm_source=20130404_ monthly_mostPopular&utm_campaign=newsletter

39. http://www.theheart.org/columns/trialsand- fibrillations-with-dr-john-mandrola/ esc-2012-is-left-atrial-appendage-closure-thetherapy- of-choice-of-3.do


Для цитирования:


Комарова А.Л. «СТАРЫЕ» И «НОВЫЕ» ВОЗМОЖНОСТИ ПРОФИЛАКТИКИ ИНСУЛЬТА У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ. Атеротромбоз. 2013;(1):44-52. https://doi.org/10.21518/2307-1109-2013-1-44-52

For citation:


Комаров А.Л. . Atherothrombosis Journal. 2013;(1):44-52. (In Russ.) https://doi.org/10.21518/2307-1109-2013-1-44-52

Просмотров: 350


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)